> top > docs > PMC:7556165 > spans > 69222-70499 > annotations

PMC:7556165 / 69222-70499 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T191 234-242 Chemical denotes peptides http://purl.obolibrary.org/obo/CHEBI_16670
T192 498-536 Chemical denotes N-(2-aminoethyl)-1aziridine-ethanamine http://purl.obolibrary.org/obo/CHEBI_145998
T193 845-852 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T386 411-419 Species denotes SARS-CoV NCBItxid:694009
T387 411-415 Species denotes SARS NCBItxid:694009
T388 633-641 Species denotes SARS-CoV NCBItxid:694009
T389 633-637 Species denotes SARS NCBItxid:694009
T390 936-940 Species denotes SARS NCBItxid:694009
T391 1091-1107 Species denotes SARS coronavirus NCBItxid:694009
T392 1091-1095 Species denotes SARS NCBItxid:694009

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T412 0-13 Sentence denotes ACE2 Blockers
T413 14-264 Sentence denotes Blockade of ACE2 receptor could be achieved through specific antibodies (Li et al., 2003), rationally designed small molecules (Dales et al., 2002; Huentelman et al., 2004; Gross et al., 2020; Pillaiyar et al., 2020) or peptides (Huang et al., 2003).
T414 265-453 Sentence denotes Although their efficacy needs to be confirmed, some of these agents are currently available on the market and have been show to effectively block SARS-CoV invasion (Li S.-R. et al., 2020).
T415 454-781 Sentence denotes For instance, the small synthetic inhibitor N-(2-aminoethyl)-1aziridine-ethanamine (NAAE) binds ACE2 active site in its closed conformation; this contact triggers the shifting of SARS-CoV S binding residues preventing the molecular interaction with targeted enzyme and the subsequent cell-cell fusion (Huentelman et al., 2004).
T416 782-980 Sentence denotes Therefore, although ACE2 catalytic site is distinct from the S-protein-binding domain, NAAE exerts dual inhibitory effects on ACE2 catalytic activity and SARS binding (Adedeji and Sarafianos, 2014).
T417 981-1277 Sentence denotes However, since a protecting role for ACE2 receptor against virus-induced acute lung injury in infections with SARS coronavirus has not been excluded (Imai et al., 2005; Kuba et al., 2005; Li S.-R. et al., 2020), the choice of ACE2 inhibition as therapeutic approach should be carefully evaluated.

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T149 1060-1064 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
1891 0-4 Gene denotes ACE2 Gene:59272
1907 26-30 Gene denotes ACE2 Gene:59272
1908 550-554 Gene denotes ACE2 Gene:59272
1909 802-806 Gene denotes ACE2 Gene:59272
1910 908-912 Gene denotes ACE2 Gene:59272
1911 1018-1022 Gene denotes ACE2 Gene:59272
1912 1207-1211 Gene denotes ACE2 Gene:59272
1913 411-419 Species denotes SARS-CoV Tax:694009
1914 633-641 Species denotes SARS-CoV Tax:694009
1915 1091-1107 Species denotes SARS coronavirus Tax:694009
1916 843-852 Gene denotes S-protein Gene:43740568
1917 498-536 Chemical denotes N-(2-aminoethyl)-1aziridine-ethanamine
1918 538-542 Chemical denotes NAAE
1919 869-873 Chemical denotes NAAE
1920 1054-1071 Disease denotes acute lung injury MESH:D055371
1921 1075-1085 Disease denotes infections MESH:D007239

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T6161 0-4 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6
T6162 26-30 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6
T6163 550-554 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6
T6164 802-806 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6
T6165 843-852 Protein denotes S-protein https://www.uniprot.org/uniprot/Q9D080|https://www.uniprot.org/uniprot/Q9BSH7|https://www.uniprot.org/uniprot/Q91X32|https://www.uniprot.org/uniprot/Q8VII4|https://www.uniprot.org/uniprot/Q5SYG4|https://www.uniprot.org/uniprot/P48819|https://www.uniprot.org/uniprot/P29788|https://www.uniprot.org/uniprot/P22458|https://www.uniprot.org/uniprot/P04004|https://www.uniprot.org/uniprot/P01141|https://www.uniprot.org/uniprot/B2R7G0
T6176 908-912 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6
T6177 1018-1022 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6
T6178 1207-1211 Protein denotes ACE2 https://www.uniprot.org/uniprot/Q9UFZ6

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T279 562-566 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T280 738-742 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T281 743-747 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T282 817-821 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T283 1040-1045 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T284 1075-1085 http://purl.obolibrary.org/obo/IDO_0000586 denotes infections

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T452 738-742 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T453 743-747 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T454 845-852 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T455 1060-1064 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T407 411-419 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T408 411-415 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T409 633-641 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T410 633-637 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T411 936-940 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T412 1054-1071 Disease denotes acute lung injury http://purl.obolibrary.org/obo/MONDO_0006502|http://purl.obolibrary.org/obo/MONDO_0015796
T414 1075-1085 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T415 1091-1095 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-sample-PD-MAT

Id Subject Object Predicate Lexical cue
T135 1060-1064 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T147 738-754 http://purl.obolibrary.org/obo/GO_0000768 denotes cell-cell fusion
T148 738-754 http://purl.obolibrary.org/obo/GO_0045026 denotes cell-cell fusion
T149 743-754 http://purl.obolibrary.org/obo/GO_0000747 denotes cell fusion
T150 913-931 http://purl.obolibrary.org/obo/GO_0003824 denotes catalytic activity

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T152 738-754 http://purl.obolibrary.org/obo/GO_0140253 denotes cell-cell fusion
T153 738-754 http://purl.obolibrary.org/obo/GO_0045026 denotes cell-cell fusion
T154 743-754 http://purl.obolibrary.org/obo/GO_0000768 denotes cell fusion
T155 743-754 http://purl.obolibrary.org/obo/GO_0000747 denotes cell fusion

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T77 1054-1071 Phenotype denotes acute lung injury http://www.orpha.net/ORDO/Orphanet_178320

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1891 0-4 Gene denotes ACE2 Gene:59272
1907 26-30 Gene denotes ACE2 Gene:59272
1908 550-554 Gene denotes ACE2 Gene:59272
1909 802-806 Gene denotes ACE2 Gene:59272
1910 908-912 Gene denotes ACE2 Gene:59272
1911 1018-1022 Gene denotes ACE2 Gene:59272
1912 1207-1211 Gene denotes ACE2 Gene:59272
1913 411-419 Species denotes SARS-CoV Tax:694009
1914 633-641 Species denotes SARS-CoV Tax:694009
1915 1091-1107 Species denotes SARS coronavirus Tax:694009
1916 843-852 Gene denotes S-protein Gene:43740568
1917 498-536 Chemical denotes N-(2-aminoethyl)-1aziridine-ethanamine
1918 538-542 Chemical denotes NAAE
1919 869-873 Chemical denotes NAAE
1920 1054-1071 Disease denotes acute lung injury MESH:D055371
1921 1075-1085 Disease denotes infections MESH:D007239

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T412 0-13 Sentence denotes ACE2 Blockers
T413 14-264 Sentence denotes Blockade of ACE2 receptor could be achieved through specific antibodies (Li et al., 2003), rationally designed small molecules (Dales et al., 2002; Huentelman et al., 2004; Gross et al., 2020; Pillaiyar et al., 2020) or peptides (Huang et al., 2003).
T414 265-453 Sentence denotes Although their efficacy needs to be confirmed, some of these agents are currently available on the market and have been show to effectively block SARS-CoV invasion (Li S.-R. et al., 2020).
T415 454-781 Sentence denotes For instance, the small synthetic inhibitor N-(2-aminoethyl)-1aziridine-ethanamine (NAAE) binds ACE2 active site in its closed conformation; this contact triggers the shifting of SARS-CoV S binding residues preventing the molecular interaction with targeted enzyme and the subsequent cell-cell fusion (Huentelman et al., 2004).
T416 782-980 Sentence denotes Therefore, although ACE2 catalytic site is distinct from the S-protein-binding domain, NAAE exerts dual inhibitory effects on ACE2 catalytic activity and SARS binding (Adedeji and Sarafianos, 2014).
T417 981-1277 Sentence denotes However, since a protecting role for ACE2 receptor against virus-induced acute lung injury in infections with SARS coronavirus has not been excluded (Imai et al., 2005; Kuba et al., 2005; Li S.-R. et al., 2020), the choice of ACE2 inhibition as therapeutic approach should be carefully evaluated.